{
  "id": 6504,
  "language": "english",
  "hallucination": "yes",
  "ground_truth_source": "Original_text",
  "dialogue_data": {
    "dialogue_metadata": {
      "inferred_relationship": "Colleagues or co-hosts",
      "inferred_vibe": "Informative and conversational"
    },
    "dialogue_turns": [
      {
        "speaker": "HostA",
        "text": "Carl Hansen, the CEO of AbCellera, was just geeking out about that on a Zoom call—our bodies can make 100 trillion different antibodies.",
        "tts_text": "Carl Hansen, the C E O of AbCellera, was just geeking out about that on a Zoom call-our bodies can make one hundred trillion different antibodies.",
        "check_worthy": true,
        "factual_label": "True",
        "evidence_snippet": "Carl Hansen, 46, is geeking out as he describes the process over Zoom. We can make 100 trillion different antibodies, he exclaims.",
        "confidence": 1.0,
        "priority": "high"
      },
      {
        "speaker": "HostB",
        "text": "Yeah, and he's not your typical biotech exec, right? He was actually a college professor until 2020 when he left to focus full-time on AbCellera.",
        "tts_text": "Yeah, and he's not your typical biotech exec, right? He was actually a college professor until twenty twenty when he left to focus full-time on AbCellera.",
        "check_worthy": true,
        "factual_label": "False",
        "evidence_snippet": "If that sounds more like a college professor than the CEO of a $13 billion (market cap) biotech company, theres a reason: Hansen was oneuntil 2019, when he left to focus on Vancouver- based AbCellera Biologics, cofounded with fellow researchers from the University of British Columbia in 2012.",
        "confidence": 1.0,
        "priority": "high"
      },
      {
        "speaker": "HostA",
        "text": "Exactly. And their approach is so different from most biotechs—they don't develop drugs all the way to market. They focus just on the discovery phase.",
        "tts_text": "Exactly. And their approach is so different from most biotechs-they don't develop drugs all the way to market. They focus just on the discovery phase.",
        "check_worthy": true,
        "factual_label": "True",
        "evidence_snippet": "AbCellera takes a vastly different approach. Instead of trying to build a vertically integrated drug company, it is focused solely on the discovery process.",
        "confidence": 1.0,
        "priority": "high"
      },
      {
        "speaker": "HostB",
        "text": "Which is huge, because that's where you identify the most promising treatments early. And it's paid off—like with Eli Lilly and bamlanivimab.",
        "tts_text": "Which is huge, because that's where you identify the most promising treatments early. And it's paid off-like with Eli Lilly and bamlanivimab.",
        "check_worthy": true,
        "factual_label": "True",
        "evidence_snippet": "In its highest-profile success to date, AbCellera examined thousands of antibodies derived from the blood of people who had recovered from Covid-19 in order to identify the antibodies that did the best job fighting the virus. It then turned over the most promising antibodies to drug company Eli Lilly.",
        "confidence": 1.0,
        "priority": "high"
      },
      {
        "speaker": "HostA",
        "text": "Right, that antibody therapy for Covid-19 got emergency FDA authorization in just months. The government's buying almost a million doses for over a billion dollars.",
        "tts_text": "Right, that antibody therapy for Covidminus nineteen got emergency F D A authorization in just months. The government's buying almost a million doses for over a billion dollars.",
        "check_worthy": true,
        "factual_label": "True",
        "evidence_snippet": "Tests found patients with mild or moderate cases had good results, and in November, the antibody received emergency-use authorization from the FDA. The federal government has contracted to purchase 950,000 doses of the drug for $1.2 billion.",
        "confidence": 1.0,
        "priority": "high"
      },
      {
        "speaker": "HostB",
        "text": "And AbCellera's gonna earn royalties around $275 million from those sales alone. That's… insane ROI for a discovery-focused model.",
        "tts_text": "And AbCellera's gonna earn royalties around two hundred seventy five dollars million from those sales alone. That's... insane R O I for a discovery-focused model.",
        "check_worthy": true,
        "factual_label": "False",
        "evidence_snippet": "Eli Lilly issued guidance in mid-December expecting up to $2 billion in revenue from Covid-19 therapeutics in 2021, the bulk of which will come from bamlanivimab; AbCellera, which booked $25 million through the end of September 2020, will earn estimated royalties of $270 million on those sales, according to Credit Suisse.",
        "confidence": 1.0,
        "priority": "high"
      },
      {
        "speaker": "HostA",
        "text": "It really proves their point—shortening development time saves millions and gets treatments to people faster. Like, they went from partnership to clinical trials in 90 days.",
        "tts_text": "It really proves their point-shortening development time saves millions and gets treatments to people faster. Like, they went from partnership to clinical trials in ninety days.",
        "check_worthy": true,
        "factual_label": "True",
        "evidence_snippet": "Clinical trials of one of those antibodies, bamlanivimab, began in Mayjust 90 days after the partnership started.",
        "confidence": 1.0,
        "priority": "high"
      },
      {
        "speaker": "HostB",
        "text": "And Hansen's now a billionaire thanks to their IPO, though he called it \"a little surreal.\" I mean, the company's valued at what, almost $5 billion?",
        "tts_text": "And Hansen's now a billionaire thanks to their I P O, though he called it a little surreal. I mean, the company's valued at what, almost five dollars billion?",
        "check_worthy": true,
        "factual_label": "True",
        "evidence_snippet": "But AbCellera, which raised $105 million from investors including Peter Thiel, the Universityof Minnesota and OrbiMed in Mayat a valuation of $4.8 billion, according to PitchBook, just six months before going publicis not interested in seeing it through from beginning to end. It feels just a little bit surreal, says Carl Hansen about becoming a billionaire.",
        "confidence": 1.0,
        "priority": "high"
      },
      {
        "speaker": "HostA",
        "text": "Yeah, and they've got big backers like Peter Thiel. But honestly, what stands out is how they work with 90 outside companies, including giants like Pfizer and Novartis.",
        "tts_text": "Yeah, and they've got big backers like Peter Thiel. But honestly, what stands out is how they work with ninety outside companies, including giants like Pfizer and Novartis.",
        "check_worthy": true,
        "factual_label": "True",
        "evidence_snippet": "It works with 90 outside businesses, including pharma giants Pfizer, Gilead and Novartis. Those companies ask the biotech to find antibodies that meet certain criteria.",
        "confidence": 1.0,
        "priority": "high"
      },
      {
        "speaker": "HostB",
        "text": "It's like drug discovery as a service. Super scalable. And with antibody treatments making up 7 of the top 10 drugs in 2018, the demand is clearly there.",
        "tts_text": "It's like drug discovery as a service. Super scalable. And with antibody treatments making up seven of the top ten drugs in twenty eighteen, the demand is clearly there.",
        "check_worthy": true,
        "factual_label": "True",
        "evidence_snippet": "Seven of the 10 top-selling drugs in 2018 were antibody treatments, including AbbVies $19 billion (net revenue) immunosuppressive drug Humira and Mercks cancer drug Keytruda, which generated $11.1 billion in 2019.",
        "confidence": 1.0,
        "priority": "high"
      },
      {
        "speaker": "HostA",
        "text": "For sure. Hansen said if Covid showed anything, it's proof that their model and tech really work. Hard to argue with those results.",
        "tts_text": "For sure. Hansen said if Covid showed anything, it's proof that their model and tech really work. Hard to argue with those results.",
        "check_worthy": true,
        "factual_label": "True",
        "evidence_snippet": "Hes more articulate about the biotechs success: If this example of Covid shows one thing, to me, its the proof point of the business model and the technology.",
        "confidence": 1.0,
        "priority": "high"
      }
    ]
  },
  "generator_model": "DeepSeek-V3.1",
  "batch_index": 2
}